GILEAD SCIENCES, INC. - 08 Aug 2025 Form 4 Insider Report for ASSEMBLY BIOSCIENCES, INC. (ASMB)

Role: 10%+ Owner
Signature: Gilead Sciences, Inc. By: /s/ Andrew D. Dickinson
Issuer symbol: ASMB
Transactions as of: 08 Aug 2025
Net transactions value: $0
Form type: 4
Filing time: 03 Oct 2025, 16:30:21 UTC
Previous filing: 06 Jun 2025
Next filing: 01 Dec 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
GILEAD SCIENCES, INC.	10%+ Owner	333 LAKESIDE DRIVE, FOSTER CITY	Gilead Sciences, Inc. By: /s/ Andrew D. Dickinson	03 Oct 2025	0000882095

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ASMB	Common Stock	Purchase		+2,295,920	+104%		4,505,391	08 Aug 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ASMB	Class A warrants to purchase Common Stock	Purchase		+1,147,960			1,147,960	08 Aug 2025	Common Stock	1,147,960	$21.60	Direct	F1, F2
transaction	ASMB	Class B warrants to purchase Common Stock	Purchase		+1,147,960			1,147,960	08 Aug 2025	Common Stock	1,147,960	$21.60	Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Pursuant to a securities purchase agreement between the Issuer and the Reporting Person, the Issuer issued and sold to the Reporting Person in a private placement 2,295,920 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), Class A warrants to purchase 1,147,960 shares of Common Stock (the "Class A Warrants"), and Class B warrants to purchase 1,147,960 shares of Common Stock (the "Class B Warrants"), at a combined price of $19.60 per share of Common Stock and accompanying one half of one Class A Warrant and one half of one Class B Warrant.
F2	The Class A Warrants are exercisable at any time after the date of issuance and expire on the earlier of (i) five years from the date of issuance, or August 11, 2030, and (ii) the date that is 30 days after the public announcement that the Issuer has completed enrollment (of at least 200 patients total) for its Phase 2 clinical study evaluating ABI-5366 vs. valacyclovir. A holder of the Class A Warrants may not exercise the Class A Warrants if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.
F3	The Class B Warrants are exercisable at any time after November 15, 2026 and expire on December 31, 2026, provided that the Class B Warrants will automatically terminate in full and be extinguished and will no longer be exercisable in the event that the Issuer publicly announces prior to November 15, 2026 that the Issuer has received at least $75 million in the aggregate of non-dilutive capital in connection with a collaboration agreement. A holder of the Class B Warrants may not exercise the Class B Warrants if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.